Our Mission: develop tumor-penetrating drugs

PDC/NDC is next-gen XDC modality: better tumor penetration, enhanced in vivo efficacy in large tumor CDX/PDX model over ADCs.

Reduced non-target distribution, suitable for optimal systemic exposure, improved safety.

Rapidly developing 5 oncology pipelines, clinical data of  SC-101 read-out in 2024.

About Conjustar

Tianjin Conjustar Biologics Co., Ltd. jointly incubated by Rehabilitation New Drug Fund and WuXi AppTec, and is dedicated to the development of novel miniaturized coupled drugs (peptide/nanoantibody-coupled drugs (PDC/NDC)).PDC/NDCs are based on the maintenance of a high target binding capacity and selectivity comparable to that of antibody-coupled drugs (ADCs).

PDCs/NDCs, while maintaining high target binding capacity and selectivity comparable to that of ADCs, have better solid tumor penetration and more suitable in vivo metabolism properties, thus providing therapeutic efficacy and safety, and are expected to benefit solid tumor patients.

History

◆ In 2024, 

   - China's first PDC drug (SC-101) approved for IND
   - SC-101 approved by US FDA
   - Second PDC drug (SC-102) approved for IND
   - Launched the construction of Zhuhai Research Center

   - PreA round of financing of 100 million RMB was obtained

◆ In February 2023, angel round of financing of 55 million RMB was obtained

◆ In August 2022, the Zhangjiang office of Conjustar was put into use
 

◆ In March 2022, 45.5 million RMB was obtained in seed funding
 

◆ In February 2022, Tianjin Conjustar Biologics Co., Ltd. was registered and established in Tianjin